SK1702001A3 - New pharmaceutical uses for NOS inhibitors - Google Patents

New pharmaceutical uses for NOS inhibitors Download PDF

Info

Publication number
SK1702001A3
SK1702001A3 SK170-2001A SK1702001A SK1702001A3 SK 1702001 A3 SK1702001 A3 SK 1702001A3 SK 1702001 A SK1702001 A SK 1702001A SK 1702001 A3 SK1702001 A3 SK 1702001A3
Authority
SK
Slovakia
Prior art keywords
formula
compound
pyridin
ylamine
pharmaceutically acceptable
Prior art date
Application number
SK170-2001A
Other languages
English (en)
Slovak (sk)
Inventor
John Adams Lowe Iii
Jolanta Nowakowski
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK1702001A3 publication Critical patent/SK1702001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK170-2001A 1998-08-11 1999-08-05 New pharmaceutical uses for NOS inhibitors SK1702001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9615298P 1998-08-11 1998-08-11
PCT/IB1999/001389 WO2000009130A2 (fr) 1998-08-11 1999-08-05 Nouvelles utilisations pharmaceutiques pour les inhibiteurs de nos

Publications (1)

Publication Number Publication Date
SK1702001A3 true SK1702001A3 (en) 2003-02-04

Family

ID=22255853

Family Applications (1)

Application Number Title Priority Date Filing Date
SK170-2001A SK1702001A3 (en) 1998-08-11 1999-08-05 New pharmaceutical uses for NOS inhibitors

Country Status (37)

Country Link
US (1) US20020151572A1 (fr)
EP (1) EP1109556A2 (fr)
JP (1) JP2002522498A (fr)
KR (1) KR20010085364A (fr)
CN (1) CN1323211A (fr)
AP (1) AP2001002067A0 (fr)
AR (1) AR020009A1 (fr)
AU (1) AU749439B2 (fr)
BR (1) BR9912906A (fr)
CA (1) CA2340200A1 (fr)
CO (1) CO5130011A1 (fr)
CR (1) CR6302A (fr)
CZ (1) CZ2001486A3 (fr)
DZ (1) DZ2867A1 (fr)
EA (1) EA200100125A1 (fr)
EE (1) EE200100084A (fr)
GE (1) GEP20043252B (fr)
GT (1) GT199900127A (fr)
HK (1) HK1041819A1 (fr)
HR (1) HRP20010099A2 (fr)
HU (1) HUP0103113A3 (fr)
ID (1) ID28227A (fr)
IL (1) IL141031A0 (fr)
IS (1) IS5814A (fr)
MA (1) MA26670A1 (fr)
NO (1) NO20010685L (fr)
NZ (1) NZ509298A (fr)
OA (1) OA11595A (fr)
PA (1) PA8479801A1 (fr)
PE (1) PE20001025A1 (fr)
PL (1) PL346842A1 (fr)
SK (1) SK1702001A3 (fr)
SV (1) SV1999000121A (fr)
TN (1) TNSN99154A1 (fr)
TR (3) TR200100434T2 (fr)
WO (1) WO2000009130A2 (fr)
YU (1) YU9601A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
WO2001062290A2 (fr) * 2000-02-22 2001-08-30 Cellegy Canada Inc. Methodes et compositions destinees a ameliorer la qualite du sommeil
CN100430399C (zh) * 2002-03-20 2008-11-05 昆士兰大学 包含一氧化氮供体和阿片样物质止痛剂的组合物和方法
WO2005007627A1 (fr) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif
WO2014138460A1 (fr) 2013-03-07 2014-09-12 Northwestern University Inhibiteurs de l'oxyde nitrique synthase neuronaux sélectifs à base de 2-aminopyridine
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
EP3215497A4 (fr) 2014-11-04 2018-11-07 Northwestern University Inhibiteurs d'oxyde nitrique synthase d'origine bactérienne et mammalienne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL329195A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of 6-phenylpyridol-2-amine
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
ES2224354T3 (es) * 1997-02-10 2005-03-01 Pfizer Products Inc. Piridinas 2-amino-6-(4-fenoxi-2-sustituido)sustituidas.
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination

Also Published As

Publication number Publication date
GEP20043252B (en) 2004-06-25
WO2000009130A3 (fr) 2000-05-18
AP2001002067A0 (en) 2001-03-31
IS5814A (is) 2001-01-16
TR200103661T2 (tr) 2002-06-21
EE200100084A (xx) 2002-08-15
AU749439B2 (en) 2002-06-27
TNSN99154A1 (fr) 2005-11-10
IL141031A0 (en) 2002-02-10
HK1041819A1 (zh) 2002-07-26
MA26670A1 (fr) 2004-12-20
DZ2867A1 (fr) 2003-12-15
NO20010685D0 (no) 2001-02-09
CR6302A (es) 2004-03-24
EA200100125A1 (ru) 2001-08-27
PE20001025A1 (es) 2000-10-11
TR200100434T2 (tr) 2001-07-23
HUP0103113A2 (hu) 2002-01-28
PL346842A1 (en) 2002-02-25
HUP0103113A3 (en) 2002-02-28
KR20010085364A (ko) 2001-09-07
HRP20010099A2 (en) 2002-02-28
EP1109556A2 (fr) 2001-06-27
WO2000009130A2 (fr) 2000-02-24
AR020009A1 (es) 2002-03-27
CA2340200A1 (fr) 2000-02-24
SV1999000121A (es) 2000-07-06
NZ509298A (en) 2005-02-25
CZ2001486A3 (cs) 2002-06-12
AU4924899A (en) 2000-03-06
ID28227A (id) 2001-05-10
NO20010685L (no) 2001-04-09
GT199900127A (es) 2001-01-30
CO5130011A1 (es) 2002-02-27
PA8479801A1 (es) 2000-09-29
OA11595A (en) 2004-08-19
US20020151572A1 (en) 2002-10-17
JP2002522498A (ja) 2002-07-23
YU9601A (sh) 2003-12-31
TR200401803T2 (tr) 2004-11-22
BR9912906A (pt) 2001-05-08
CN1323211A (zh) 2001-11-21

Similar Documents

Publication Publication Date Title
JP3411271B2 (ja) Ｎｏｓ阻害剤であり縮合環置換基を含む２−アミノピリジン類
EP0946512B1 (fr) Derives de 6-phenylpyridyl-2-amine utilises comme inhibiteurs de nos
EP1289996B1 (fr) Heteroaryldiazabicycloalkanes comme ligands du recepteur cholinergique nicotinique
SK113998A3 (en) 6-phenylpyridyl-2-amine derivatives
WO2001053263A1 (fr) Antagonistes de la corticoliberine
CZ257892A3 (en) Derivative of 1,4-benzodioxan, process of its preparation and a pharmaceutical preparation in which said derivative is comprised
WO1996011930A1 (fr) Derives de pyridinyluree actifs dans le traitement des troubles du systeme nerveux central
AU2935300A (en) New pharmaceutical combinations for nos inhibitors
SK1702001A3 (en) New pharmaceutical uses for NOS inhibitors
JPS60188385A (ja) 置換ヘキサヒドロアリ−ルキノリジン類
SK12022001A3 (sk) 2-aminopyridíny obsahujúce ako substituenty kondenzované kruhové skupiny
US20040229911A1 (en) New pharmaceutical combinations for NOS inhibitors
AP1208A (en) 2-Aminopyridines containing fused ring substituents
JP2016528269A (ja) １ｈ−ピラゾロ［３，４−ｂ］ピリジン誘導体及び増殖性障害の治療のための当該誘導体の医薬組成物
US7012078B2 (en) 2-aminopyridines containing fused ring substituents
MXPA01001548A (en) New pharmaceutical uses for nos inhibitors
MXPA01010677A (en) Azaindole derivatives for the treatment of depression